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Abstract
Polycystic ovary syndrome (PCOS) is recognized as the most common reproductive disorder in women. Obesity is believed to play 
a central role in the development of PCOS, as many women with this condition are reported to be overweight or obese. A strong 
correlational relationship exists between PCOS and obesity. This paper examines the relationship between PCOS and obesity in 
order to determine whether PCOS causes obesity as opposed to obesity causes metabolic changes that lead to PCOS.  Analysis was 
conducted by reviewing and comparing many studies related to the topic . Factors such as insulin resistance, hyperandrogenemia 
and body fat distribution were examined in obese and non-obese PCOS subjects.  Most studies included in this review could not 
conclusively determine whether PCOS contributed to obesity or vice versa.  The important points raised in the literature showed 
that obesity could be an important factor to predict PCOS.   In women who are predisposed to PCOS, the metabolic and hormonal 
issues that are present such as insulin resistance and hyperandrogenism, can lead to weight gain and eventually obesity. Obesity 
in turn can exacerbate the symptoms of PCOS such as further metabolic issues and reproductive abnormalities.
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Sara Leah Rosenberg
Sara Leah Rosenberg graduated with a B.S. degree in Biology in June 2019 and is going to attend the Touro 
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Introduction
Polycystic ovary syndrome (PCOS) is a common metabolic and 
endocrine disorder   effecting 15- 20% of women of reproductive 
age. This disorder, originally known as Stein-Leventhal syndrome, 
was discovered in 1935. Its clinical features include obesity, hirsut-
ism, acne, infertility, and oligomenorrhea. PCOS is also attribut-
ed to several hormonal and metabolic disturbances, including 
increased androgen production and disordered gonadotropin 
secretion leading to menstrual irregularity, hirsutism, and infer-
tility. Aside from interfering with reproductive function, PCOS 
also disrupts the metabolism of women, affecting insulin action 
and β-cell function, increasing the risk for glucose intolerance and 
type 2 diabetes (Liu et al. 2017; Raisbeck 2009). 
The origin of PCOS remains unclear, but research has shown that 
one of the characteristics of this disorder is the excess produc-
tion of androgens in the ovaries (Alanbay et al. 2012). Androgen 
secretion is the result of abnormal response of the ovary to go-
nadotropins, insulin and insulin-like hormones such as insulin-like 
growth factor-1 (IGF-1), which enhances LH-stimulated andro-
gen secretion by theca cells. Although the condition is not life 
threatening, the lack of treatment could lead to more serious 
health issues in the future, such as increased risk of infertility, 
dysfunctional bleeding, endometrial carcinoma, obesity, type 2 di-
abetes mellitus, dyslipidemia, hypertension, and increased risk for 
cardiovascular diseases (Raisbeck 2009).
Among the risk factors associated with PCOS, overweight (body 
mass index (BMI) 25–29.9 kg/m2) and obesity (BMI ≥30 kg/m2) 
have been considered as major contributing factor to overall 
health concerns among women worldwide. Obesity has also 
been a determined as a contributing factor to reproductive health 
problems such as anovulation. As body weight increases, incidence 
of anovulation also increases significantly.  Another contributor to 
reproductive dysfunction is the accumulation of abdominal fat, 
indicating a higher risk associated with insulin resistance (IR). IR 
in obese women has been associated with anovulation and in-
creased androgen secretion (Kuchenbecker et al. 2011). 
Several studies relate obesity as a risk factor of PCOS (Reinehr 
et al. 2005; Soydinc et al. 2013). Some studies report that 
overweight and obesity incidence in females with PCOS is as 
high as 80%.The mechanisms by which obesity influences PCOS 
‘ pathophysiology and clinical expression are not fully under-
stood, but obesity is independently associated with IR (Rojas 
et al. 2014) and sex steroid imbalances that may lead to an in-
creased risk of menstrual irregularities and hyperandrogenemia, 
similar to PCOS symptoms (Pasquali and Gambineri 2006). On 
the other hand, others proposed that regardless of physical con-
dition PCOS could occur. PCOS may develop in women with a 
BMI in any range including both underweight and overweight 
women. (McEwen and Hartmann 2018). The consistent associ-
ation between PCOS and obesity suggests a biological basis for 
this observation. Obesity exacerbates many of the reproductive 
and metabolic abnormalities associated with PCOS. Considering 
the close association between PCOS and obesity, the question 
remains whether PCOS causes obesity or does obesity cause 
metabolic changes that lead to PCOS?
Method
A critical appraisal of the literature on the topic was conducted. 
A search for related studies was conducted using the access of 
Touro’s library in various databases, such as EBSCO, ProQuest, 
PubMed, MEDLINE, CINAHL, Cochrane Reviews, and Sage on-
line publications. Other information was sourced from Google 
Scholar. Keywords used to obtain the relevant documents in-
cluded PCOS, obesity, insulin resistance, reproductive health 
abnormalities and PCOS, metabolic anomalies and PCOS. In 
addition, a library search was also conducted for references in 




One of the main contributors to PCOS is insulin resistance (IR). 
Insulin is an important hormone produced by beta cells in the 
pancreas. It is responsible for the metabolism of glucose reduc-
tion of blood glucose levels by stimulating the glucose intake in 
insulin-sensitive tissue such as those found in the skeletal muscles. 
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IR is common and an early predictor of metabolic diseases. IR 
is the “inability of insulin to optimally stimulate the transport of 
glucose into the body’s cell” (McEwen and Hartmann 2018). 
Several studies investigated IR among women diagnosed with 
PCOS regardless of BMI. Fasting insulin levels in both lean and 
obese women diagnosed with PCOS were determined and com-
pared with control subjects. A total of 64 women with PCOS 
and 20 healthy subjects were evaluated using anthropometry, 
oral glucose tolerance tests, and insulin tolerance tests. Glucose 
levels were then measured using glucoseoxidase, whereas serum 
C-peptide and insulin levels were obtained using immunoradio-
metric assays. Insulin sensitivity and β-cell function were derived 
from fasting values of insulin and glucose or from oral glucose 
tolerance tests or insulin tolerance tests measurements. Results 
revealed that β-cell function is elevated in both lean and obese 
women with PCOS. In obese women suffering from PCOS, re-
duced values in fasting state-derived disposition index were 
found, whereas lean women suffering from PCOS were found 
to have increases in these variables when oral glucose tolerance 
tests were determined. The authors suggested that insulin hyper-
secretion may be an important mechanism in the pathogenesis 
of PCOS. Further, prevention of serious metabolic complications 
could be achieved with the early screening of impaired insulin 
action and secretion in women with PCOS (Vribikova et al. 2002).
Under normal conditions, the relationship between insulin 
secretion and sensitivity is constant to maintain normal glucose 
tolerance. If the sensitivity of insulin varies, the secretion of 
insulin also changes. Obese and lean females with PCOS have 
lower production of insulin sensitivity compared to the amount 
of insulin secreted in response to blood glucose levels than 
weight-matched healthy women (Dunaif 1999).
Another study investigated the association of IR to the in-
creased risk for cardiovascular disease among women with 
PCOS. They examined the effects of IR on myocardial microcir-
culation and peripheral artery function in patients with PCOS. 
A total of 55 women (28 with PCOS without IR, 18 with PCOS 
and IR, and 11 normal controls) participated in the study. All 
subjects were examined using high-resolution vascular ultra-
sound and real time myocardial contrast echocardiography 
(RTMCE).  Results indicated that women with PCOS and IR had 
depressed replenishment velocity and myocardial blood flow 
reserve, but no changes in endothelial dysfunction or intima–
media thickness. By contrast, women with PCOS but without IR 
were found to have isolated depression in replenishment veloc-
ity, suggesting that this condition could be an early indicator of 
myocardial flow abnormality (Aldrighi et al. 2015).
IR and hyperinsulinemia are exacerbated in obese individu-
als. The accumulation of excess intra-abdominal fat increases 
IR because of its sensitivity to lipolysis and releases more free 
fatty acids in the circulation and produces several cytokines 
(i.e. tumor necrosis factor-α [TNF-α], IL-6, leptin, resistin) that 
occur in IR (Carpentier 2008). Circulating free fatty acids can ac-
cumulate in non-adipose tissues, causing lipotoxicity and insulin 
resistance. In obesity, IR is also related to TNF-α that enhanced 
serine phosphorylation of IRS-1 and inhibits insulin receptor 
signaling (Hotamisligil et al. 1996). Furthermore, IR associated to 
obesity induces leptin resistance and reduced adiponectin levels, 
which are two factors that may reduce fatty acid oxidation and 
promote lipotoxicity (Carpentier 2008).
The mechanisms causing insulin resistance in PCOS have 
many similarities with those seen in relation to visceral adiposity 
(Kabir et al. 2005). Excess free fatty acids derived from lipolysis/
hydrolysis of acylglycerol in adipocytes accumulate in the hepatic 
portal veins, and this induces hepatic dysfunction. This condition 
contributes to elevated glucose secretion, stimulates pancreatic 
insulin secretion and glucose uptake in adipose tissue (Bergman 
et al. 2000). This specific insulin resistance, also known as hepatic 
insulin resistance, is only present in obese women with PCOS and 
not in healthy women of comparable body weight (Dunaif 1999). 
The results of these studies demonstrate only a correlational re-
lationship rather than a causal one between obesity and PCOS 
on glucose production, which may highlight an important factor 
of the pathogenesis of glucose intolerance.
Another approach was taken to determine the effects of insulin 
resistance on PCOS. Researchers investigated the relationship be-
tween neuropeptide Y (NPY) and insulin resistance. NPY enhanc-
es appetite and is structurally and immunologically similar to the 
pancreatic polypeptide, which has 36 amino acids. NPY is found in 
the central and peripheral nervous system. NPY controls nutrient 
intake and body weight. NPY also has an inhibitor effect on the 
hypothalamohypophyseal-ovarian axis. A total of 45 patients with 
PCOS and 44 healthy reproductive age individuals participated in 
the study. At early follicular phase in patients with PCOS, insulin, 
fasting blood sugar, follicle-stimulating hormone (FSH), luteinizing 
hormone (LH), prolactin, testosterone, dehydroepiandrosterone 
sulfate (DHEA-S), thyroid stimulating hormone (TSH), cortisol, 
estradiol, and NPY levels were determined. Meanwhile, insulin, 
fasting blood sugar, prolactin, DHEA-S, TSH, cortisol, and 17-OH 
progesterone levels were obtained from the control group. 
Fasting insulin levels and homeostatic model assessment for IR 
(HOMA-IR) were more elevated in obese patients with PCOS 
than in patients with normal weight and healthy controls. NPY 
levels were also higher in obese-overweight women with PCOS 
compared with the control and normal weight patients, but they 
were not statistically significant. NPY levels did not differ in pa-
tients with and without IR (Koseci et al. 2019). 
A study confirms the strong association between metabolic 
aberrations such as IR and PCOS. IR is clearly manifested among 
women with weight gain and who are genetically predisposed 
to develop PCOS. Conversely, weight reduction of women 
with PCOS reduces the negative impact of PCOS. Excluding 
obesity and fat mass, PCOS is related to metabolic aberrations 
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such as IR, dyslipidemia, and non-alcoholic fatty liver disease. 
Mechanisms attributed to the development of IR in PCOS have 
been established in previous studies. For example, the relation-
ship between visceral adipose tissue and IR has been proven 
in other studies.  Further investigation suggests that abdominal 
mass in women is proportional to the total fat mass regardless 
of PCOS status. This condition alone cannot completely ex-
plain the occurrence of IR in PCOS, however, fat distribution in 
women suggests an explanation as to why IR worsens as women 
with PCOS gain weight (Barber et al. 2016). 
Biochemical Indicators
Many studies have used biochemical indicators as an approach 
to better understanding PCOS. One examined the impact of 
hyperandrogenemia on IR.  Research has shown that impaired 
metabolism of glucose and IR is partially explained by high an-
drogen concentrations. Women with PCOS have both hyperan-
drogenemia and IR. By activating androgen receptors, testoster-
one caused IR in subcutaneous adipocytes. This impairs glucose 
metabolism due to defects in downstream protein phosphory-
lation, kinase-C protein, which usually mediates insulin’s impact 
on glucose transport (Corbould 2007).
In another study, the rationale for IR in PCOS patients was 
investigated. Adipocytes of women with PCOS had enhanced 
glycogen synthase kinase-3 (GSK3) action. Consequently, insu-
lin-stimulated glucose transport was impaired, and IR developed. 
Furthermore, overexpression of GSK3 promoted androgen bio-
synthesis through direct stimulation of P450c17 enzyme activity 
(Chang et al. 2008). Results from these two studies verify that 
continuous exposure to androgens impairs insulin action and 
contributes to the development of IR.
Androgens have an important role in body composition be-
cause they determine the location of fat stored in the body. 
Androgens influence adipocyte function and distribution by the 
inhibition of adipocyte differentiation, which modulates lipoly-
sis and lipogenesis (Dicker et al. 2004). In general, males have 
greater distribution of body fat in the upper portion of the 
body, whereas females accumulate fat in the posterior region of 
the body. Among women, distribution of adipose tissue differs 
between women with and without PCOS. Adipose tissues of 
women with PCOS have been found to be dispersed viscerally 
similar to that of males. For a given waist circumference, abdom-
inal subcutaneous fat in women has been found to be higher 
than that of men regardless of age (Kuk et al. 2005). 
To determine the possible developmental origins of PCOS, a 
model was constructed to trace the pathophysiology of PCOS 
involving excess androgens (including the signs and symptoms) 
at every stage of the disease. Androgen excess occurs in a vi-
cious perpetual cycle. The gene expression of excess androgens 
in utero results in high LH and insulin concentrations, enhanc-
ing the enzyme activities in theca cells and encouraging the 
progression of primordial to preantral and small antral follicles. 
These interactions elevate androgen levels. The process is com-
pleted and revived when a female with excess androgen procre-
ates and bears a female fetus, suggesting the genetic path of the 
syndrome (Homburg 2010). 
Body fat distribution was researched among females with and 
without PCOS. The subjects were matched for age and BMI. 
They also looked at the connection between concentrations 
of androgen, IR, and fat distribution. A total of 31 women with 
PCOS and 29 healthy subjects as controls participated in the 
study. Women with PCOS demonstrated higher fat mass value 
in the trunk and arms. Fat accumulation occurs during puberty 
in the hips, thighs, and buttocks and is preserved throughout 
women’s fertile stage.  However, there is more upper body fat 
distribution for females who have been diagnosed with meta-
bolic illnesses and PCOS. Excess androgens were ascribed to 
this disease. As a consequence of obesity, the impact of high 
androgens is increased due to lower concentrations of sex hor-
mone-binding globulin (SHBG) and greater concentrations of 
freely circulating bioactive androgens. Insulin increases testos-
terone’s impacts by suppressing SHBG. It functions as a co-go-
nadotropin and inhibits SHBG’s hepatic synthesis excluding sex 
steroid impacts that contribute to hyperandrogenism. Insulin 
stimulates the synthesis of ovarian androgen and decreases the 
concentrations of SHBG circulation due to the high concentra-
tions of complete serum and free testosterone. Consequently, 
there was more upper body fat distribution among females with 
PCOS. This research suggests that lowering the distribution and 
structure of fat may be useful in decreasing PCOS-related met-
abolic aberrations (Cosar 2008).
The relationship between abdominal and upper-body fat, 
glucose and lipid metabolism markers, and serum androgens 
in women with PCOS were investigated. The study includ-
ed 40 women aged 19-49 years with BMI 18.7 – 53.8 kg/m2. 
The participants had at least two of the following features of 
PCOS, namely, oligomenorrhoea or amenorrhea, clinical and/
or biochemical evidence of hyperandrogenemia, and polycystic 
ovaries in ultrasound imaging. All obese subjects had increased 
abdominal fat. A significant correlation was found between obe-
sity and serum fasting glucose and insulin levels. The same result 
was found in homeostatic model assessment index of IR. A posi-
tive correlation was observed between estimates of obesity and 
serum triglycerides and between obesity and blood pressure. 
Subsequently, the researchers confirmed direct positive cor-
relations between free androgen index, body weight and BMI 
(Kozakowski and Zgliczynski 2013). 
Others also recorded the elevated incidence of upper-body 
obesity as evidenced by enhanced waist circumference and 
waist-hip ratio compared with BMI-matched control females, 
confirming the same results. Studies using dual-energy x-ray ab-
sorptiometry have disclosed enhanced accumulation of core fat 
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in females with PCOS in accordance with these results (Douchi 
et al. 1995). Chronic exposure in females with PCOS to greater 
concentrations of testosterone may alter the distribution of 
body fat in these females. Studies of androgen administration 
in non-obese females to male transsexuals leading to increased 
visceral fat and adverse impact on insulin sensitivity provide 
support for this hypothesis (Elbers et al. 1997). In both obese 
and normal-weight females, exposure to androgens increases 
visceral fat (Rosenfield 1999). In rats, administering a single 
elevated dose of testosterone early in life contributes to the 
growth of insulin resistance and centralization as an adult of ad-
ipose tissue mass (Nilsson et al. 1998). Early androgen exposure 
may adversely affect future distribution of body fat with higher 
core fat accumulation.  Studies of isolated abdominal fat cells 
from females with PCOS have shown that there is a preferential 
abdominal accumulation of adipose tissue in both obese and 
non-obese females with PCOS compared to control females 
(Dunaif et al. 1992). In obese females with PCOS, femoral adipo-
cytes are fewer than reproductively ordinary females, consistent 
with a change to the distribution of upper-body fat in females 
with PCOS. Observation of the increased distribution of viscer-
al adipose tissue in PCOS can be ascribed to the impact of an-
drogens, their metabolism, and tissue-specific steroid receptor 
expression (Blouin 2009). Since this visceral fat is biologically 
active (Kuchenbecker et al. 2011), it most probably contributes 
to further metabolic and endocrine disorders in PCOS.
Women with upper-body obesity have PCOS symptoms such 
as reduced sensitivity to insulin and are at greater danger of car-
diac illness and diabetes (Vague 1956). It was observed that in 
females with upper-body obesity, the incidence of diabetes, hy-
pertension, and atherosclerosis was greater than in lower-body 
obesity. Furthermore, it has been noted that the incidence of 
upper body obesity rises in females after menopause and fe-
males with upper body obesity tend to have hyperandrogenic 
characteristics such as hirsutism.
PCOS is defined by anomalies in the hormone releasing go-
nadotropin (GnRH), a pulse generator that leads to a rise in the 
release of LH over the follicle stimulating hormone (FSH). These 
abnormalities are obesity-independent. Healthy obese females 
have no defects in levels of 24-hour LH and FSH. Excess insulin 
stimulates hypothalamic GnRH secretion up to a certain point, 
thus inducing gonadotropin secretion (especially LH) from pitu-
itary cells, which in turn stimulates the development of andro-
gen in the ovaries. When hyperinsulinemia is found, the pituitary 
is led to secrete big quantities of LH, which tends to boost the 
LH / FSH ratio. LH stimulates androgens synthesis in the ovaries, 
and an absence of FSH impairs the aromatization of androgens 
in granulosa cells to estrogens. These modifications cause the 
tiny ovarian follicles to grow and hinder the maturation needed 
for the development of the dominant follicle that then appears 
as polycystic ovaries (Dunaif 2003).
Obesity and PCOS
Although it is true that obesity is a risk factor, the disease has 
also been diagnosed in lean females, although reproductive is-
sues are generally discovered more frequently in obese females, 
regardless of PCOS.  Obese females were more probable to 
have irregular menstrual cycles and anovulatory infertility com-
pared to ordinary weight females. The risk of anovulatory infer-
tility rises by 24 kg / m2 at BMI and continues to increase as BMI 
rises. But even a slight proportion of decrease in body fat can 
restore these women’s menstrual cycles.
To understand which comes first, obesity or PCOS, studies 
have investigated this relationship in girls and adolescents. It was 
noted that girls with a high BMI in childhood had an increased 
risk of oligomenorrhea and a diagnosis of PCOS in young 
adulthood (age 24), yet the possibility that features of PCOS 
were already present in these girls cannot be excluded. The re-
searchers investigated if PCOS (or its features) in adolescents 
is predictive of later class III obesity. Despite not using pelvic 
ultrasonography, PCOS was diagnosed using the Rotterdam cri-
teria in 12 (40%) of 30 oligomenorrheic girls at age 14 years. 
Of these girls, 33% displayed class III obesity by 24 years of age 
versus 8.4% of girls without PCOS. Other predictors of class 
III obesity included low sex hormone binding globulin (SHBG), 
oligomenorrhea, high childhood insulin levels, increased cFT and 
MetS, all of which are recognized as PCOS phenotypes (Glueck 
et al. 2011). Meanwhile, others conducted a prospective study 
on 244 randomly selected postmenarchal girls from a large pop-
ulation-based birth cohort to investigate the influence of obe-
sity on the development of abnormal ovarian morphology. They 
found PCOS in 61.1% of the obese girls, but only in 32.1% of 
the normal- weight girls, suggesting that obesity is a contributing 
factor (Hickey et al. 2011). These studies illustrate that obesity 
and PCOS are correlative in their pathogenesis.
Additional trials explored the differences between obese and 
nonobese Croatian females with PCOS in clinical, hormonal and 
metabolic characteristics. The research included a total of 74 
obese and 208 nonobese females with PCOS. Obese females 
with PCOS were discovered to be at greater danger of develop-
ing oligomenorrhea, but at a lower risk of developing hirsutism 
and acne.  Furthermore, obese subjects were more likely to 
develop hyperandrogenemia, insulin resistance, hypercholester-
olemia, hypertriglyceridemia, and high serum CRP concentra-
tions than nonobese females. Among obese females with PCOS, 
metabolic problems were more probable to happen than their 
healthy counterparts (Baldani et al. 2013).
Especially in females with upper-body obesity, the discovery 
of enhanced androgen production in obese females was re-
vealed. Androgen clearance rates have also risen, however, the 
circulation of bioavailable androgens remains within the normal 
range. Similarly, due to hyperinsulinemia, SHBG concentrations 
are decreased in this state. SHBG concentrations in females 
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with or without PCOS are negatively associated with the cir-
culating insulin concentrations or with the degree of insulin 
resistance. Reducing insulin concentrations with diazoxide in 
obese PCOS females, a drug that only reduces insulin secretion 
without altering insulin sensitivity, has been discovered to in-
crease SHBG concentrations. This finding indicates that insulin 
may directly suppress the secretion of liver SHBG and com-
pensatory hyperinsulinemia as opposed to IR, explaining low 
concentrations of SHBG in obese females with PCOS. Due to 
reduced SHBG secretion induced by insulin, hyperandrogene-
mia is further exacerbated. Consequently, obesity-related hy-
perinsulinemia is a significant contributor to ovarian production 
of androgens in PCOS. By directly stimulating steroidogenesis 
in ovarian theca and granulosa cells, hyperinsulinemia may lead 
to hyperandrogenemia. Similar studies have been done on mice 
and have shown that liver and muscle cells display insulin resis-
tance during constant hyperinsulinemia, while insulin receptors 
remain sensitive in pituitary and ovarian cells, an adaptation that 
improves the secretion of pituitary hormones and ovarian an-
drogen production (Nestler, et al 1991). This observation was 
used as a model to describe the insulinemic contribution to the 
advanced androgen production to PCOS in obese women.
A systematic and meta-analytical review on existing literature 
was conducted to determine the prevalence of obesity among 
women diagnosed with PCOS. Moreover, the researchers in-
tended to determine whether ethnicity, geographic regions, 
and the diagnostic criteria of PCOS had confounding effects on 
this relationship.  A total of 106 studies conducted before 2010 
were included in the review. Among them, only 35 studies were 
included in the meta-analysis because the rest did not include a 
control group. They found that compared to non-obese women, 
obese women with PCOS were more likely to have poor clinical 
reproductive presentation. Evidence also suggested that PCOS 
contributed to obesity. Increased androgen levels in women re-
gardless of PCOS status were found to affect the appetite for 
high-fat and carbohydrate rich foods. However, other metabolic 
factors such as hyperinsulinemia, reduced postprandial thermo-
genesis, and basal metabolic rate and alterations contributed 
to weight gain in women with PCOS. However, the question 
remains whether PCOS contributed to obesity or vice versa. 
Some studies showed that women with PCOS had a greater 
tendency to accumulate fat in the upper body. This effect had 
also been found even in normal weight women.  Overall, it was 
concluded that women with PCOS were more likely to be over-
weight or obese compared to healthy counterparts. Caucasian 
with PCOS had greater risk for obesity than Asian women with 
PCOS (Lim et al. 2012).
Conclusion
In most health issues around the world, obesity is a signifi-
cant characteristic. Such observation does not exclude PCOS. 
However, most of the research in this review has not been able 
to determine conclusively whether PCOS contributed to obe-
sity or vice versa. However, the significant points raised in the 
literature showed that PCOS could be predicted by obesity as a 
significant factor. Overweight or obese females were at a high-
er risk of PCOS than ordinary weight females, but the weight 
problem does not exclude ordinary weight females from getting 
PCOS and its problems.
Researchers found that an elevated BMI among girls during 
childhood increases the risk of oligomenorrhea and a diagnosis 
of PCOS in young adulthood (age 24). They also investigated 
whether PCOS or its features were present in these adoles-
cents, which could predict later class III obesity during adult-
hood. Among 12 of 30 oligomenorrheic girls at age 14, 33% of 
the girls were predicted to have class III obesity in a decade 
compared to 8.4% without PCOS (Glueck et al. 2011). Another 
study found PCOS in 61.1% of the obese girls, but only in 32.1% 
of the normal- weight girls, suggesting that obesity is a contrib-
uting factor (Hickey et al. 2011). These studies illustrated that 
obesity and PCOS are correlative in their pathogenesis. 
By contrast, it was found that both lean and obese women 
with PCOS had elevated βF regardless of BMI. Lean PCOS sub-
jects had elevated DI values when OGTTs were determined. 
Aside from body weight, insulin hypersecretion could be an im-
portant mechanism in the pathogenesis of PCOS. Early screening 
of insulin action in women with PCOS regardless of BMI could 
prevent serious metabolic complications (Vribikova et al. 2002). 
Meanwhile, others found that both obese and lean women with 
PCOS have lower product of insulin sensitivity compared to the 
amount of insulin secreted in response to blood glucose levels 
than weight-matched healthy women (Dunaif 1999).
Nevertheless, being overweight or obese is a significant con-
tributory factor that aggravates the conditions of women with 
PCOS. IR among women with PCOS had been found to increase 
the risk of cardiovascular disease. Women with PCOS and IR 
demonstrated depressed replenishment velocity and MBFR, but 
no changes in endothelial dysfunction or IMT. However, women 
with PCOS but without IR were found to have isolated de-
pression in replenishment velocity, suggesting that this condi-
tion could be an early indicator of myocardial flow abnormality 
(Aldrighi et al. 2015).
Other studies indicated that only a correlational relationship 
(rather than a causal one) exists between obesity and PCOS on 
glucose production. It was noted that IR and hyperinsulinemia 
are intensified in obese individuals. Accumulation of excess in-
tra-abdominal fat increases IR because of its sensitivity to lipoly-
sis and releases more FFAs in circulation and produces several 
cytokines (i.e. tumor necrosis factor-α [TNF-α], IL-6, leptin, 
resistin) that occur in IR (Carpentier 2008). The mechanisms 
causing IR in PCOS have many similarities with those seen in 
relation to visceral adiposity (Kabir et al. 2005). A specific IR 
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also known as hepatic IR is only present in obese women with 
PCOS (Dunaif 1999). 
Researchers concluded that evidence in the literature suggested 
that PCOS contributed to obesity. Increased androgen levels in 
women regardless of PCOS status were found to affect the appe-
tite for high-fat and carbohydrate rich foods. However, other met-
abolic factors such as hyperinsulinemia, reduced postprandial ther-
mogenesis, and basal metabolic rate and alterations contributed to 
weight gain in women with PCOS. They also noted that women 
with PCOS were more likely to be overweight or obese compared 
to healthy counterparts. Caucasian with PCOS had greater risk for 
obesity than Asian women with PCOS (Lim et al. 2012).
The literature reviewed yielded significant information on 
PCOS. However, no conclusive evidence pointed to obesity 
as the main cause of PCOS or PCOS could cause weight gain. 
Biochemical and metabolic features that were impaired because 
of PCOS were suggested in these studies. Metabolic rate anom-
alies found in women with PCOS were more likely to cause 
their weight gain. Aside from weight gain, other PCOS features 
such as insulin hypersecretion, overproduction of androgens, 
reduced SHBG, relationship between IR and myocardial flow 
abnormality have been mentioned as contributing factors to 
more serious health issues among women with PCOS. 
PCOS is not an exclusive condition for females who are over-
weight or obese. Normal weight females also exhibited PCOS, 
especially females deemed to be PCOS candidates due to bio-
chemical and metabolic dysfunctions. Due to the confounding 
factors connected with body fat and PCOS, weight gain is feasi-
ble for these females. Nevertheless, it was discovered that more 
than half of the females with PCOS studied in this research 
were overweight or obese. To determine the connection be-
tween body mass and PCOS, a more comprehensive research 
should be performed.
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